JP Morgan Chase’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-283,819
| Closed | -$10.9M | – | 7855 |
|
|
2023
Q2 | $10.9M | Buy |
283,819
+125,855
| +80% | +$3.23M | ﹤0.01% | 2225 |
|
|
2023
Q1 | $3.66M | Buy |
157,964
+5,979
| +4% | +$143K | ﹤0.01% | 3067 |
|
|
2022
Q4 | $3.98M | Sell |
151,985
-164,846
| -52% | -$3.65M | ﹤0.01% | 3015 |
|
|
2022
Q3 | $6.23M | Buy |
316,831
+184,955
| +140% | +$3.71M | ﹤0.01% | 2546 |
|
|
2022
Q2 | $2.31M | Sell |
131,876
-1,274
| -1% | -$20K | ﹤0.01% | 3421 |
|
|
2022
Q1 | $2.18M | Buy |
133,150
+2,985
| +2% | +$40.6K | ﹤0.01% | 3682 |
|
|
2021
Q4 | $2.12M | Sell |
130,165
-1,114
| -0.8% | -$15.9K | ﹤0.01% | 3816 |
|
|
2021
Q3 | $1.68M | Sell |
131,279
-29,600
| -18% | -$390K | ﹤0.01% | 3926 |
|
|
2021
Q2 | $2.27M | Sell |
160,879
-4,387
| -3% | -$70.2K | ﹤0.01% | 3708 |
|
|
2021
Q1 | $2.57M | Sell |
165,266
-22,895
| -12% | -$373K | ﹤0.01% | 3510 |
|
|
2020
Q4 | $2.98M | Sell |
188,161
-8,243
| -4% | -$124K | ﹤0.01% | 3201 |
|
|
2020
Q3 | $2.27M | Sell |
196,404
-12,868
| -6% | -$172K | ﹤0.01% | 3144 |
|
|
2020
Q2 | $2.42M | Sell |
209,272
-90,124
| -30% | -$1.24M | ﹤0.01% | 2977 |
|
|
2020
Q1 | $4.1M | Sell |
299,396
-54,464
| -15% | -$644K | ﹤0.01% | 2435 |
|
|
2019
Q4 | $2.09M | Buy |
353,860
+61,710
| +21% | +$335K | ﹤0.01% | 3352 |
|
|
2019
Q3 | $1.55M | Buy |
292,150
+9,337
| +3% | +$62K | ﹤0.01% | 3573 |
|
|
2019
Q2 | $2.47M | Buy |
282,813
+187,433
| +197% | +$2.85M | ﹤0.01% | 3234 |
|
|
2019
Q1 | $1.9M | Sell |
95,380
-227
| -0.2% | -$3.96K | ﹤0.01% | 3365 |
|
|
2018
Q4 | $1.26M | Buy |
95,607
+1,666
| +2% | +$33.3K | ﹤0.01% | 3595 |
|
|
2018
Q3 | $3.45M | Buy |
93,941
+2,086
| +2% | +$67K | ﹤0.01% | 3049 |
|
|
2018
Q2 | $3.21M | Sell |
91,855
-2,087
| -2% | -$80K | ﹤0.01% | 3032 |
|
|
2018
Q1 | $4.37M | Sell |
93,942
-6,350
| -6% | -$232K | ﹤0.01% | 2693 |
|
|
2017
Q4 | $3.76M | Buy |
100,292
+27,102
| +37% | +$1.18M | ﹤0.01% | 2906 |
|
|
2017
Q3 | $3.99M | Sell |
73,190
-1,280
| -2% | -$76.1K | ﹤0.01% | 2723 |
|
|
2017
Q2 | $4.24M | Buy |
74,470
+55,059
| +284% | +$2.76M | ﹤0.01% | 2585 |
|
|
2017
Q1 | $1.04M | Sell |
19,411
-1,891
| -9% | -$107K | ﹤0.01% | 3389 |
|
|
2016
Q4 | $1.21M | Sell |
21,302
-1,529
| -7% | -$92.5K | ﹤0.01% | 3344 |
|
|
2016
Q3 | $1.42M | Buy |
22,831
+306
| +1% | +$21.6K | ﹤0.01% | 2977 |
|
|
2016
Q2 | $1.27M | Buy |
22,525
+4,435
| +25% | +$269K | ﹤0.01% | 3054 |
|
|
2016
Q1 | $1.16M | Sell |
18,090
-984
| -5% | -$79.6K | ﹤0.01% | 3002 |
|
|
2015
Q4 | $2.68M | Buy |
19,074
+2,399
| +14% | +$326K | ﹤0.01% | 2605 |
|
|
2015
Q3 | $1.61M | Sell |
16,675
-45
| -0.3% | -$5.36K | ﹤0.01% | 2852 |
|
|
2015
Q2 | $2.54M | Buy |
+16,720
| New | +$2.76M | ﹤0.01% | 2771 |
|
JP Morgan Chase's KDNY Position: Q3 2023 in Review
JP Morgan Chase sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 283,819 shares — an estimated $10.9M sold.
JP Morgan Chase first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $10.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- JP Morgan Chase reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- JP Morgan Chase sold 283,819 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $10.9M.
- JP Morgan Chase first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- JP Morgan Chase's Chinook Therapeutics, Inc. Common Stock position peaked at $10.9M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.